Claude C. Schulman Bücher

Reprint European Urology 1999, Vol. 35, No. 5-6 Prostate cancer is a prime target for chemoprevention studies because of its long latency, high incidence and known risk factors; furthermore, hormonal dependency and precursor lesions are well documented. To identify suitable populations for evaluation of potential chemopreventive agents and for future chemopreventive intervention, risk factors (such as the presence of early premalignant lesions and genetic predisposition) should be well characterized. Therefore, identification and characterization of intermediate biomarkers and their validation as surrogate endpoints for cancer incidence in clinical chemoprevention trials are significant components in the development of chemopreventive agents. Promising chemopreventive drugs of the prostate include retinoids, antiandrogens, antioestrogens, steroid aromatase inhibitors, 5a-reductase inhibitors, vitamins D and E, selenium, lycopene and 2-difluoromethylomithine. As a new concept in prostate cancer, chemoprevention should have a significant impact in the future on the incidence and mortality of this leading cancer threat in men.

An examination of treatment of patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS), which results in so-called symptomatic BPH. The text explores the development of pharmacological treatments, the range of medical therapies available and quality of life.

Presents the proceedings of an international symposium on the management of prostate cancer. It offers guidance to physicians for making the best possible management choices.

Presents the proceedings of a satellite symposium, held at the XIIth Congress of the European Association of Urology, held in Paris during September 1996.